These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2559854)

  • 1. Chronic opioid antagonist treatment: assessment of receptor upregulation.
    Yoburn BC; Sierra V; Lutfy K
    Eur J Pharmacol; 1989 Nov; 170(3):193-200. PubMed ID: 2559854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous development of opioid tolerance and opioid antagonist-induced receptor upregulation.
    Yoburn BC; Sierra V; Lutfy K
    Brain Res; 1990 Oct; 529(1-2):143-8. PubMed ID: 2178026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic supersensitivity and opioid receptor upregulation in the mouse.
    Yoburn BC; Nunes FA; Adler B; Pasternak GW; Inturrisi CE
    J Pharmacol Exp Ther; 1986 Oct; 239(1):132-5. PubMed ID: 3020228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased analgesic potency of morphine and increased brain opioid binding sites in the rat following chronic naltrexone treatment.
    Yoburn BC; Goodman RR; Cohen AH; Pasternak GW; Inturrisi CE
    Life Sci; 1985 Jun; 36(24):2325-32. PubMed ID: 2989632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic d-amphetamine inhibits opioid receptor antagonist-induced supersensitivity.
    Duttaroy A; Billings B; Candido J; Yoburn BC
    Eur J Pharmacol; 1992 Oct; 221(2-3):211-5. PubMed ID: 1330622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissociation of opioid receptor upregulation and functional supersensitivity.
    Chang SC; Lutfy K; Sierra V; Yoburn BC
    Pharmacol Biochem Behav; 1991 Apr; 38(4):853-9. PubMed ID: 1651519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of delta receptor mediation of supraspinal opioid analgesia by in vivo protection against the beta-funaltrexamine antagonist effect.
    Sánchez-Blázquez P; Garzón J
    Eur J Pharmacol; 1989 Jan; 159(1):9-23. PubMed ID: 2565240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mu-opioid receptor up-regulation and functional supersensitivity are independent of antagonist efficacy.
    Sirohi S; Kumar P; Yoburn BC
    J Pharmacol Exp Ther; 2007 Nov; 323(2):701-7. PubMed ID: 17698975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of nimodipine on opioid antagonist-induced upregulation and supersensitivity.
    Lee SC; Yoburn BC
    Pharmacol Biochem Behav; 2000 Jun; 66(2):347-51. PubMed ID: 10880689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: relationship to receptor selectivity.
    Yoburn BC; Shah S; Chan K; Duttaroy A; Davis T
    Pharmacol Biochem Behav; 1995; 51(2-3):535-9. PubMed ID: 7667382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of opioid receptor subtypes correlates with potency changes of morphine and DADLE.
    Yoburn BC; Luke MC; Pasternak GW; Inturrisi CE
    Life Sci; 1988; 43(16):1319-24. PubMed ID: 2845219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic administration of morphine and naltrexone up-regulate[3H][D-Ala2,D-leu5]enkephalin binding sites by different mechanisms.
    Danks JA; Tortella FC; Long JB; Bykov V; Jacobson AE; Rice KC; Holaday JW; Rothman RB
    Neuropharmacology; 1988 Sep; 27(9):965-74. PubMed ID: 2847072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment of rats with the irreversible mu-receptor antagonist, beta-FNA, fails to prevent naltrexone-induced upregulation of mu-opioid receptors.
    Rothman RB; Long JB; Bykov V; Jacobson AE; Rice KC; Holaday JW
    Neuropharmacology; 1990 Sep; 29(9):805-10. PubMed ID: 1963479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative antagonism by naltrexone and naloxone of mu, kappa, and delta agonists.
    Takemori AE; Portoghese PS
    Eur J Pharmacol; 1984 Sep; 104(1-2):101-4. PubMed ID: 6094203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
    Ward SJ; Takemori AE
    J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of mu-opioid receptor antisense on morphine potency and antagonist-induced supersensitivity and receptor upregulation.
    Shah S; Duttaroy A; Chen BT; Carroll J; Yoburn BC
    Brain Res Bull; 1997; 42(6):479-84. PubMed ID: 9128924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naltrexone-induced opiate receptor supersensitivity.
    Zukin RS; Sugarman JR; Fitz-Syage ML; Gardner EL; Zukin SR; Gintzler AR
    Brain Res; 1982 Aug; 245(2):285-92. PubMed ID: 6289965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of the opioid receptor complex by the chronic administration of morphine: a biochemical marker related to the development of tolerance and dependence.
    Rothman RB; Long JB; Bykov V; Xu H; Jacobson AE; Rice KC; Holaday JW
    Peptides; 1991; 12(1):151-60. PubMed ID: 1646998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic naltrexone differentially affects supraspinal delta-opioid receptor-mediated antinociception.
    Kest B; Lee CE; Jenab S; Kao B; Inturrisi CE
    Eur J Pharmacol; 1998 Mar; 345(1):47-53. PubMed ID: 9593593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperthermic response of the cat to intraventricular injection of the opioid delta-receptor agonist D-Ala2-D-Leu5-enkephalin.
    Pang IH; Bernardini GL; Clark WG
    Brain Res Bull; 1984 Aug; 13(2):263-8. PubMed ID: 6093942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.